CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Sees Significant Growth in Short Interest

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 843,600 shares, a growth of 188.2% from the February 28th total of 292,700 shares. Based on an average trading volume of 685,500 shares, the days-to-cover ratio is currently 1.2 days. Approximately 34.6% of the company’s stock are short sold.

CERo Therapeutics Trading Down 1.8 %

Shares of NASDAQ:CERO opened at $0.75 on Friday. CERo Therapeutics has a 12-month low of $0.66 and a 12-month high of $376.00. The business’s fifty day simple moving average is $1.61 and its 200-day simple moving average is $7.25.

Hedge Funds Weigh In On CERo Therapeutics

An institutional investor recently raised its position in CERo Therapeutics stock. ARCH Venture Management LLC grew its position in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) by 550.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,393,561 shares of the company’s stock after buying an additional 7,949,265 shares during the period. CERo Therapeutics accounts for about 0.2% of ARCH Venture Management LLC’s portfolio, making the stock its 9th largest position. ARCH Venture Management LLC owned approximately 626.24% of CERo Therapeutics worth $564,000 at the end of the most recent reporting period. Institutional investors own 29.64% of the company’s stock.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.